Product Details
Product Name:
Sacituzumab govitecan |
CAS No.:
1491917-83-9 |
Purity:
95% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Sacituzumab govitecan |
Description | Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity [1]. |
In vivo | Sacituzumab govitecan (IMMU-132) administered at a dose of 17.5 mg/kg biweekly for four weeks demonstrated significant antitumor activity in mice bearing human gastric cancer xenografts [1]. |
Storage | store at low temperature | Shipping with blue ice. |
Keywords | Sacituzumab govitecan | IMMU 132 | IMMU132 |
Inhibitors Related | Disitamab vedotin | Tisotumab vedotin | Cantuzumab ravtansine | Glembatumumab vedotin | Depatuxizumab MMAE | Trastuzumab duocarmazine | Depatuxizumab mafodotin | Brentuximab vedotin | N3-PEG4-C2-NHS ester | Trastuzumab deruxtecan |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:928821-40-3
$0.00 / 25mg
-
CAS:1601479-87-1
$1520.00 / 25mg
-
CAS:567-75-9
$2500.00 / 100mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$163.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |